Neurodegeneración
Aug 19, 2026
Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review
Molecular Biomarkers and Sex-Dimorphic Trajectories of Cognitive Impairment in African Parkinson's Disease Cohorts: A Precision Biomedicine Perspective
Abstract
Cognitive impairment (PD-MCI) and neuropsychiatric manifestations represent major clinical hurdles in Parkinson's disease (PD), often presenting accelerated progression in understudied populations across Africa. Emerging evidence points to complex cellular pathologies, including toxic $\alpha$-synuclein oligomerization, mitochondrial electron transport chain failure, and neuroinflammatory cascade activation, as driver mechanisms for non-motor cognitive decline. Concurrently, biological sex acts as a pivotal modifier of these pathophysiological trajectories. Estrogenic signaling, neuroprotective steroidogenesis, and X-linked genetic escape mechanisms modulate proteostatic resilience and microglial activation in a sex-specific manner. This article evaluates the molecular drivers, emerging fluid biomarkers (such as plasma Neurofilament Light Chain [NfL] and phosphorylated tau species), and predictors of PD-associated cognitive decline within African populations. By embedding Sex-and-Gender-Based Analysis (SGBA) into biomarker discovery and molecular profiling, we highlight how sexual dimorphism influences neurodegenerative susceptibility and stress response pathways. Understanding these intersections is imperative for establishing equitable precision medicine approaches, fine-tuning biomarker diagnostic thresholds, and developing targeted neuroprotective therapeutics tailored to global diversity.
Introduction & Cellular Mechanisms
Parkinson’s disease (PD) is fundamentally characterized by the progressive degeneration of dopaminergic neurons within the substantia nigra pars compacta (SNpc). However, the systemic spread of pathological pathology—spanning cortical, limbic, and subcortical structures such as the nucleus basalis of Meynert—drives the manifestation of cognitive impairment and neuropsychiatric symptoms (NPS). In African cohorts, where diagnostic lag and unique genetic landscapes exist, understanding the primary molecular nodes of cognitive decline is crucial for targeted clinical intervention.
At the cellular level, PD-associated cognitive pathology is driven by a triad of organelle dysfunction, proteostatic failure, and neuroinflammation:
1. Proteostatic Failure and Lysosomal Dysfunction: The central hallmark of PD cognitive decline is the accumulation of misfolded $\alpha$-synuclein ($\alpha$-syn) aggregates. Disruption of the autophagy-lysosomal pathway (ALP)—frequently linked to genetic variations in *GBA1* (encoding glucocerebrosidase) and *LRRK2*—prevents the clearance of toxic pre-formed fibrils (PFFs). Lysosomal membrane permeabilization triggers the cytosolic release of cathepsins and exacerbates neuronal toxicity.
2. Mitochondrial Bioenergetic Deficits: Neuronal energy demands rely heavily on oxidative phosphorylation. Dysregulation of complex I of the mitochondrial electron transport chain leads to electron leakage, elevated generation of reactive oxygen species (ROS), and depolarization of the inner mitochondrial membrane. Impaired mitophagy (regulated via PINK1/Parkin pathways) causes the retention of damaged mitochondria, initiating intrinsic apoptotic cascades mediated by cytochrome c release.
3. Neuroinflammation and Glial Activation: Pathological $\alpha$-syn species bind to Toll-like receptors (TLR2/TLR4) on microglial cells, initiating nuclear factor kappa B (NF-$\kappa$B) translocation and assembling the NLRP3 inflammasome. This pathway drives the cleavage and release of pro-inflammatory cytokines, including interleukin-1 beta (IL-1$\beta$) and interleukin-18 (IL-18). Chronic astroglial and microglial reactivity damages extracellular matrix integrity, disrupts the blood-brain barrier (BBB), and accelerates cholinergic neuronal loss.
Emerging biomarkers, such as plasma Neurofilament Light Chain (NfL)—a marker of axonal structural degradation—and seed amplification assays (SAA) for misfolded $\alpha$-syn, offer objective measures of neurodegeneration. Integrating these tools with longitudinal clinical profiling in African populations is essential for defining specific risk trajectories.
```
[Pathological α-Synuclein Fibrils]
│
├───> TLR2/TLR4 Activation ───> NF-κB / NLRP3 Inflammasome ───> IL-1β, IL-18 Release
│
├───> Autophagy-Lysosomal Failure (GBA1/LRRK2) ───> Proteostatic Collapse
│
└───> Mitochondrial Complex I Inhibition ───> ROS Generation & Mitophagy Failure
```
Sex-Dimorphic Regulation & Translational Implications
Biological sex significantly influences the susceptibility, clinical phenotype, and progression rate of PD and its cognitive sequelae. Women frequently exhibit a lower initial risk of PD onset compared to men, yet they often face unique trajectories regarding neuropsychiatric manifestations, affective disorders, and dyskinesia progression. A robust SGBA framework is essential to unraveling the biological underpinnings of these dimorphic phenotypes.
1. Hormonal Neuroprotection and Mitochondrial Bioenergetics:
17$\beta$-estradiol (E2) exerts neuroprotective effects through intracellular estrogen receptors (ER$\alpha$ and ER$\beta$) and the membrane-bound G-protein coupled estrogen receptor 1 (GPER1). Estrogen signaling upregulates anti-apoptotic factors (e.g., Bcl-2), enhances mitochondrial complex I efficiency, and directly scavenging ROS. In females, this signaling pathway mitigates $\alpha$-synuclein toxicity and maintains synaptic density in cortical networks. The post-menopausal drop in systemic E2 levels represents a vulnerable window during which neuroinflammatory cascades can accelerate cognitive decline.
2. X-Chromosome Gene Dosage and Epigenetic Architecture:
The X chromosome contains a high density of genes involved in immune regulation and neural function. Genes that escape X-chromosome inactivation (XCI), such as *KDM6A* (a histone demethylase) and *USP9X* (a deubiquitinase regulating $\alpha$-synuclein trafficking), show higher expression levels in females. This differential dosage can enhance neuroinflammatory resilience or modulate proteostatic responses to protein aggregation.
3. Sex Differences in Neuroinflammation and Biomarker Signatures:
Microglial cells display sex-specific transcriptional signatures. Male microglia tend toward a pro-inflammatory phenotype under baseline metabolic stress, producing higher levels of TNF-$\alpha$ and IL-6. Conversely, female microglia maintain a neuroprotective phenotype longer, though this state can undergo rapid dysregulation post-menopause. Consequently, circulating fluid biomarkers like NfL, phosphorylated tau (p-tau181, p-tau217), and glial fibrillary acidic protein (GFAP) demonstrate sex-specific baseline concentrations and trajectory slopes, requiring sex-adjusted cut-off values for diagnostic precision in African cohorts.
4. Translational SGBA Integration in African Biomarker Studies:
Translating biomarker discoveries into clinical utility across sub-Saharan Africa requires accounting for genetic heterogeneity, endemic co-morbidities, and sex-specific social drivers of health. Stratifying genomic, proteomic, and clinical datasets by biological sex prevents the obscuration of sex-linked risk alleles (e.g., variant penetrance of *GBA1* or *PRKN*) and ensures that neuroprotective therapeutic interventions are optimized for both male and female physiology.
Conclusions & Clinical Outlook
Addressing cognitive impairment and neuropsychiatric symptoms in Parkinson's disease across diverse African populations requires a shift toward precision biomedicine. Expanding biomarker discovery—utilizing high-sensitivity assay platforms for fluid NfL, p-tau species, and $\alpha$-synuclein seed amplification—will be crucial for identifying subclinical neurodegeneration prior to overt cognitive collapse.
Furthermore, embedding sex-and-gender-based analysis (SGBA) directly into the design of preclinical and clinical trials is essential. Understanding the interplay between estrogenic signaling, X-chromosome gene dosage, microglial immunometabolism, and genetic diversity will enable the development of targeted, sex-specific neuroprotective strategies. Establishing rigorous, geographically representative, and sex-stratified biobanks across Africa will form the cornerstone of global health equity in neurodegenerative research.
Key Insights
References
1. Okubadejo, N. U., et al. (2024). Prevalence, predictors, and emerging biomarkers for cognitive impairment and neuropsychiatric manifestations in Parkinson's disease in Africa: A systematic review. *Movement Disorders Clinical Practice*, 11(3), 245–258. https://doi.org/10.1002/mdc3.13476
2. Cerri, S., Blandini, F., & Modena, M. (2019). Sex differences in Parkinson's disease: Highlight on pathology and pathogenesis. *Frontiers in Neuroendocrinology*, 55, 100781. https://doi.org/10.1016/j.yfrne.2019.100781
3. Ashton, N. J., et al. (2021). Plasma neurofilament light chain and phosphorylated tau 181 as biomarkers for cognitive decline in neurodegenerative diseases: A cross-cohort validation study. *Nature Medicine*, 27(9), 1602–1610. https://doi.org/10.1038/s41591-021-01448-x
